Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$301.33 USD

301.33
417,020

+1.19 (0.40%)

Updated Apr 18, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Align Technology (ALGN) Up 30% YTD: Will the Rally Continue?

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN), driven by recent strategic alliance and geographic expansion.

Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.

Shaun Pruitt headshot

Bear of the Day: Align Technology (ALGN)

by Shaun Pruitt

Undoubtedly, investors are hoping that the end-of-the-year rally can continue for the broader stock market but the recent spike in Align Technology (ALGN) shares appears to be overdone.

Align's (ALGN) Invisalign Palatal Expander System Gets FDA Nod

by Zacks Equity Research

Align's (ALGN) Invisalign Palatal Expander is the company's first direct 3D-printed orthodontic device. It offers a safe, pleasant and clinically effective alternative to traditional palatal expanders.

Align's (ALGN) New Launches Aid, Macroeconomic Woes Linger

by Zacks Equity Research

Align Technology (ALGN) performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others.

Align Technologies (ALGN) Secures Updated Medical Device License

by Zacks Equity Research

Align Technologies' (ALGN) Invisalign Palatal Expander system receives an updated medical device license from Health Canada.

Align Technology (ALGN) Moves 11.1% Higher: Will This Strength Last?

by Zacks Equity Research

Align Technology (ALGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

David Bartosiak headshot

Bear of the Day: Becton, Dickenson and Co (BDX)

by David Bartosiak

Earnings have been retreating on this Bear of the Day.

Here's Why You Should Retain Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.

What's in Store for Cooper Companies (COO) in Q4 Earnings?

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

Align Technology (ALGN) Up 14% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN), led by its strong global presence.

CNMD or ALGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CNMD vs. ALGN: Which Stock Is the Better Value Option?

Align Technology (ALGN) Q3 Earnings Miss, Operating Margin Up

by Zacks Equity Research

Align Technology's (ALGN) Q3 fiscal 2023 performance reflects revenue growth across all regions.

Compared to Estimates, Align Technology (ALGN) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Align Technology (ALGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Align Technology (ALGN) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Align Technology (ALGN) delivered earnings and revenue surprises of -5.31% and 3.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.

Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Align (ALGN) Gains From New Launches, Strategic Partnerships

by Zacks Equity Research

Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.

Align Technology (ALGN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Add Cencora (COR) to Your Portfolio Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

STERIS' (STE) Improved Volume, New Buyouts Drive Growth

by Zacks Equity Research

On the capital equipment side for STERIS (STE), the easing of supply-chain issues and reduced lead times are boosting shipments.

PetMeds (PETS) to Advance Pet Care With New Collaboration

by Zacks Equity Research

PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.